Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Jean Marie Boher"'
Autor:
Leonor Lopez Almeida, Eric Lambaudie, Clément Brun, Braticevic, Goetgheluck, Charlène Villaron, Patricia Marino, Christophe Zemmour, Cécile Bannier, Jihane Pakradouni, Jean-Marie Boher, Patrick Ben Soussan
Publikováno v:
International Journal of Gynecological Cancer
International Journal of Gynecological Cancer, 2021, 31 (6), pp.920-924. ⟨10.1136/ijgc-2020-002128⟩
International Journal of Gynecological Cancer, 2021, 31 (6), pp.920-924. ⟨10.1136/ijgc-2020-002128⟩
BackgroundPatients undergoing neoadjuvant chemotherapy before surgery for advanced ovarian cancer may have impaired functional capacity, nutritional status, and emotional well-being.Primary objective(s)TRAINING-01 aims to determine if a connected pre
Autor:
Arnaud Guille, Jihane Pakradouni, Max Chaffanet, Séverine Garnier, Christelle Levy, Marie Robert, Jean Marie Boher, Anthony Gonçalves, Cecile Vicier, Cornel Popovici, José Adélaïde, Daniel Birnbaum, Florence Dalenc, Patrick Sfumato, Nadine Carbuccia, Renaud Sabatier, Keyvan Rezai, Nicolas Isambert, Emmanuelle Charafe-Jauffret, François Bertucci, Magali Provansal
Publikováno v:
European Journal of Cancer
European Journal of Cancer, 2021, 159, pp.205-214. ⟨10.1016/j.ejca.2021.09.040⟩
European Journal of Cancer, 2021, 159, pp.205-214. ⟨10.1016/j.ejca.2021.09.040⟩
International audience; Background: Hormone-resistant HER2-negative or triple-negative advanced breast cancers (ABC) are routinely treated with paclitaxel chemotherapy. LY2780301 is a dual inhibitor of p70 ribosomal protein S6 kinase and AKT. The TAK
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8522dd2e4d78727ec43433cf5ba566f
https://hal.science/hal-03622797
https://hal.science/hal-03622797
Autor:
Pernelle Lavaud, Etienne Suc, Gwenaelle Gravis, Alain Ravaud, Gael Deplanque, Igor Latorzeff, Florence Joly, Nicole Tubiana-Mathieu, Muriel Habibian, Jean-Marie Boher, Brigitte Laguerre, Christian Platini, Stéphane Oudard, Jean Marc Ferrero, Jean-François Berdah, Stéphane Culine, Frederic Rolland, Frank Priou, Clemence Legoupil, Damien Pouessel, Ivan Krakowski, Philippe Beuzeboc, Ali Hasbini, Jérôme Dauba, Jean-Christophe Eymard, Claude El Kouri, Marjorie Baciuchka, Stéphanie Foulon, Remy Delva, Loic Mourey, Michel Soulié, Claude Linassier, Guilhem Bousquet, Christine Theodore, Sylvie Zanetta, Gabrielle Tergemina-Clain, Karim Fizazi, Jean-Pascal Machiels
Publikováno v:
European Urology
European Urology, 2017, ⟨10.1016/j.eururo.2017.09.022⟩
European Urology, 2017, ⟨10.1016/j.eururo.2017.09.022⟩
Background Androgen deprivation therapy (ADT) plus docetaxel is the standard of care in fit men with metastatic castration-naive prostate cancer (mCNPC) following results from GETUG-AFU 15, CHAARTED, and STAMPEDE. No data are available on the efficac
Autor:
Florence Joly, Muriel Habibian, Manish Kohli, Jean Marie Boher, Christopher Sweeney, Jorge A. Garcia, Glenn Liu, Gwenaelle Gravis, Joel Picus, Mario J. Eisenberger, Michel Soulié, David M. Jarrard, Maha Hussain, Michael A. Carducci, Karim Fizazi, Nicholas J. Vogelzang, Robert Dreicer, Stéphane Oudard, Yu-Hui Chen, Robert S. DiPaola
Publikováno v:
European Urology
European Urology, Elsevier, 2018, 73 (6), pp.847-855. ⟨10.1016/j.eururo.2018.02.001⟩
European Urology, 2018, 73 (6), pp.847-855. ⟨10.1016/j.eururo.2018.02.001⟩
European Urology, Elsevier, 2018, 73 (6), pp.847-855. ⟨10.1016/j.eururo.2018.02.001⟩
European Urology, 2018, 73 (6), pp.847-855. ⟨10.1016/j.eururo.2018.02.001⟩
International audience; BACKGROUND:Docetaxel (D) at the time of starting androgen deprivation therapy (ADT) for metastatic castrate naive prostate cancer shows a clear survival benefit for patients with high-volume (HV) disease. It is unclear whether
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::268d1e460fcbece64024709d2d4be616
https://www.hal.inserm.fr/inserm-02092595
https://www.hal.inserm.fr/inserm-02092595
Autor:
Gilles Houvenaeghel, Monique Cohen, Pédro Raro, Jérémy De Troyer, Christine Tunon de Lara, Pierre Gimbergues, Tristan Gauthier, Christelle Faure-Virelizier, Véronique Vaini-Cowen, Stéphane Lantheaume, Claudia Regis, Emile Darai, Vivien Ceccato, Gauthier D’Halluin, Francesco Del Piano, Richard Villet, Eva Jouve, Bassoodéo Beedassy, Pierrick Theret, Philippe Gabelle, Cécile Zinzindohoue, Pierre Opinel, Catherine Marsollier-Ferrer, Caroline Dhainaut-Speyer, Pierre-Emmanuel Colombo, Eric Lambaudie, Agnès Tallet, Jean-Marie Boher, Others investigators (SERC trial group)
Publikováno v:
BMC Cancer
BMC Cancer, 2018, 18, pp.1153. ⟨10.1186/s12885-018-5053-7⟩
BMC Cancer, BioMed Central, 2018, 18, pp.1153. ⟨10.1186/s12885-018-5053-7⟩
BMC Cancer, Vol 18, Iss 1, Pp 1-14 (2018)
BMC Cancer, 2018, 18, pp.1153. ⟨10.1186/s12885-018-5053-7⟩
BMC Cancer, BioMed Central, 2018, 18, pp.1153. ⟨10.1186/s12885-018-5053-7⟩
BMC Cancer, Vol 18, Iss 1, Pp 1-14 (2018)
Background Three randomized trials have concluded at non inferiority of omission of complementary axillary lymph node dissection (cALND) for patients with involved sentinel node (SN). However, we can outline strong limitations of these trials to vali
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93b489f553d5abce5b605db53daf00b9
https://hal.sorbonne-universite.fr/hal-01980063/document
https://hal.sorbonne-universite.fr/hal-01980063/document
Autor:
Gwenaelle Gravis, Florence Joly, Muriel Habibian, Patricia Marino, Karim Fizazi, Stéphane Culine, Patrick Sfumato, Jean-Marie Boher, Stéphane Oudard
Publikováno v:
European journal of cancer (Oxford, England : 1990). 84
Background Early chemotherapy has recently become a new standard of care for patients with metastatic castrate-naive prostate cancer (mCNPC). The survival benefit is evident in patients with high-volume disease, but less clear in those with low-volum
Autor:
Audrey, Monneur, Anthony, Goncalves, Marine, Gilabert, Pascal, Finetti, Carole, Tarpin, Christophe, Zemmour, Jean-Marc, Extra, Agnès, Tallet, Eric, Lambaudie, Jocelyne, Jacquemier, Gilles, Houvenaeghel, Jean-Marie, Boher, Patrice, Viens, François, Bertucci
Publikováno v:
Oncotarget
Purpose Inflammatory breast cancer (IBC) is a very aggressive form of breast cancer, as compared to locally advanced breast cancer (LABC). Neoadjuvant chemotherapy followed by surgery is the standard treatment in both cases. Whether IBC is less chemo
Autor:
Anthony Gonçalves, Richard Villet, Laura Sabiani, Emile Daraï, P.-E. Colombo, Alexandre de Nonneville, Charles Coutant, Nicolas Chopin, Sylvia Giard, Fabien Reyal, Christophe Scherer, Roman Rouzier, Xavier Muracciole, Eric Lambaudie, Christophe Zemmour, Monique Cohen, Renaud Sabatier, Jean Marie Boher, Jean Rémi Garbay, Pierre Gimbergues, Gilles Houvenaeghel, François Bertucci, Jean Marc Classe
Publikováno v:
Breast Cancer Research and Treatment
Breast Cancer Research and Treatment, Springer Verlag, 2017, 162 (2), pp.307-316. ⟨10.1007/s10549-017-4136-5⟩
Breast Cancer Research and Treatment, 2017, 162 (2), pp.307-316. ⟨10.1007/s10549-017-4136-5⟩
Breast Cancer Research and Treatment, Springer Verlag, 2017, 162 (2), pp.307-316. ⟨10.1007/s10549-017-4136-5⟩
Breast Cancer Research and Treatment, 2017, 162 (2), pp.307-316. ⟨10.1007/s10549-017-4136-5⟩
Benefit of adjuvant trastuzumab-based chemotherapy for node-positive and/or1 cm human epidermal growth factor receptor 2-positive (HER2+) breast carcinomas has been clearly demonstrated in randomized clinical trials. Yet, evidence that adjuvant chemo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52707bebec92efc50af588bef69c2935
https://hal-amu.archives-ouvertes.fr/hal-03623719
https://hal-amu.archives-ouvertes.fr/hal-03623719
Autor:
Charlotte Proudhon, E. Charafe-Jaufret, A-C. Hardy-Bessard, Aurélie Autret, J-M Ferrero, J.-C. Eymard, Florence Dalenc, M. Campone, François-Clément Bidard, François Bertucci, Alain Lortholary, Patrick Soulié, Thomas Bachelot, Fabrice Andre, Jacques Bonneterre, Jean-Yves Pierga, Patrice Viens, Jean-Marie Boher, Christelle Levy, Gilles Romieu, Joseph Gligorov, Pierre Kerbrat, Thierry Petit, Jérôme Lemonnier, Marie-Ange Mouret-Reynier, Florence Lerebours
Publikováno v:
Annals of Oncology
Annals of Oncology, Elsevier, 2017, 28, pp.mdw535. ⟨10.1093/annonc/mdw535⟩
Annals of Oncology, 2017, 28, pp.mdw535. ⟨10.1093/annonc/mdw535⟩
Annals of Oncology, Elsevier, 2017, 28, pp.mdw535. ⟨10.1093/annonc/mdw535⟩
Annals of Oncology, 2017, 28, pp.mdw535. ⟨10.1093/annonc/mdw535⟩
International audience; Background: We present a pooled analysis of predictive and prognostic values of circulating tumour cells (CTC) and circulating endothelial cells (CEC) in two prospective trials of patients with inflammatory breast cancer (IBC)
Autor:
Patrice Viens, Carole Tarpin, Eric Lambaudie, Jocelyne Jacquemier, Jean-Marc Extra, Anthony Gonçalves, Gilles Houvenaeghel, Jean-Marie Boher, Pascal Finetti, Agnès Tallet, Christophe Zemmour, François Bertucci, Marine Gilabert, Audrey Monneur
Publikováno v:
Oncotarget
Oncotarget, Impact journals, 2017, 8 (39), pp.66019-66032. ⟨10.18632/oncotarget.19732⟩
Oncotarget, Impact journals, 2017, 8 (39), pp.66019-66032. ⟨10.18632/oncotarget.19732⟩
// Audrey Monneur 1 , Anthony Goncalves 1, 2 , Marine Gilabert 1 , Pascal Finetti 1 , Carole Tarpin 1 , Christophe Zemmour 3 , Jean-Marc Extra 1 , Agnes Tallet 4 , Eric Lambaudie 5 , Jocelyne Jacquemier 6 , Gilles Houvenaeghel 2, 5 , Jean-Marie Boher
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c05e0a102192c4628e6e69f5f73f4ef
https://doi.org/10.18632/oncotarget.19732
https://doi.org/10.18632/oncotarget.19732